CXBS (Corix Bioscience) Debt-to-Equity: 0.01 (As of Sep. 2017)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Corix Bioscience Debt-to-Equity?

Corix Bioscience CXBS -99.00% Debt-to-Equity is 0.01 as of Sep. 2017.

Corix Bioscience's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2017 was $0.05 Mil. Corix Bioscience's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2017 was $0.00 Mil. Corix Bioscience's Total Stockholders Equity for the quarter that ended in Sep. 2017 was $3.56 Mil. Corix Bioscience's debt to equity for the quarter that ended in Sep. 2017 was 0.01.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Corix Bioscience's Debt-to-Equity or its related term are showing as below:

CXBS's Debt-to-Equity is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.275
* Ranked among companies with meaningful Debt-to-Equity only.

Corix Bioscience  (OTCPK:CXBS) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Corix Bioscience Debt-to-Equity Related Terms

Corix Bioscience Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Corix Bioscience's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corix Bioscience Debt-to-Equity Chart

Corix Bioscience Annual Data
Trend Jan09 Jan10 Jan11 Jan12 Jan13 Jan14 Jan15 Dec16
Debt-to-Equity
Get a 7-Day Free Trial 0.00 -0.47 -0.22 0.00 1.15

Corix Bioscience Quarterly Data
Oct12 Jan13 Apr13 Jul13 Oct13 Jan14 Apr14 Jul14 Oct14 Jan15 Apr15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.21 1.15 N/A 0.00 0.01

CXBS vs BKIT, YBAO, HSTI: Debt-to-Equity Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Corix Bioscience's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Corix Bioscience Debt-to-Equity vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Corix Bioscience's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Corix Bioscience's Debt-to-Equity falls into.


Corix Bioscience Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Corix Bioscience's Debt to Equity Ratio for the fiscal year that ended in Dec. 2016 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.074 + 5.077) / 4.476
=1.15

Corix Bioscience's Debt to Equity Ratio for the quarter that ended in Sep. 2017 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.05 + 0) / 3.558
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of 0.01 mean?
Corix Bioscience (CXBS) has a Debt-to-Equity of 0.01 as of Sep. 2017. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Corix Bioscience and its competitors.
Is Corix Bioscience's Debt-to-Equity too high?
Corix Bioscience's current Debt-to-Equity is 0.01. The Drug Manufacturers industry median Debt-to-Equity is 0.28. Corix Bioscience's value of 0.01 is 96.4% below this industry median.
How does Corix Bioscience's Debt-to-Equity compare to BKIT and YBAO?
Corix Bioscience's Debt-to-Equity of 0.01 can be compared against companies in the Drug Manufacturers industry. The industry median Debt-to-Equity is 0.28. Corix Bioscience's value of 0.01 is 96.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Corix Bioscience's current Debt-to-Equity of 0.01 is 96.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Corix Bioscience and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Corix Bioscience's current Debt-to-Equity is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corix Bioscience stock overvalued right now?
Corix Bioscience (CXBS) has a current Debt-to-Equity of 0.01. The current Debt-to-Equity is 0.01 and 96.4% below the Drug Manufacturers industry median of 0.28. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Corix Bioscience (CXBS), the current Debt-to-Equity is 0.01 as of Sep. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Corix Bioscience Business Description

Address 18662 MaCaurther Boulevard, Suite 200, Irvine, CA, USA, 85085
Corix Bioscience Inc is a United States-based research and development firm of cannabidiol (CBD) products and treatments. It is engaged in the business of producing organic CBD oil used for medical applications and treatments. In addition, the group is also focused on the production of tetrahydrocannabivarin oil. The company is focused on operations in Oregon, California, and Nevada, United States.